Medical Milestone Achieved By This Health Company For New Treatment
Abeona Therapeutics Receives Priority Review from FDA for Pioneering Gene Therapy.
In a major medical and scientific milestone, Abeona Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel).
Pz-cel is Abeona's investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). This significant development could potentially provide a new treatment avenue for patients suffering from RDEB, a rare skin disorder characterized by blister formation in response to minor injury or friction.
The Journey to FDA Approval
The journey towards this point has been marked by rigorous research, clinical trials, and regulatory discussions. Earlier this year, Abeona Therapeutics held a positive Pre-BLA Meeting with FDA for EB-101, paving the way for the BLA submission. The FDA has previously granted EB-101 regenerative medicine advanced therapy, breakthrough therapy, orphan drug, and rare pediatric disease designations.
Speaking on the development, an Abeona spokesperson said, "This is a significant step forward in our commitment to bring innovative therapies to patients with RDEB. The acceptance of the BLA and granting of priority review underscores the potential of pz-cel as a treatment for RDEB."
The Significance of FDA's Priority Review
The granting of Priority Review by the FDA is a significant stamp of approval, as it is a designation given to drugs that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.
Looking Ahead
While the FDA's priority review represents a significant milestone, it's important to note that it does not guarantee approval. The FDA's decision is expected in the coming months and will be eagerly watched by patients, healthcare professionals, and investors alike.
The acceptance of the BLA for pz-cel by the FDA marks a promising development in the field of gene therapy. As we look to the future, the potential approval of pz-cel could pave the way for more innovative therapies to treat rare and debilitating diseases.
Disclaimer: This article contains links to third-party websites. The author/website may earn a commission for purchases made through these links. However, the majority of the content provided is not promotional and aims to inform and provide value to the reader.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.